Incyte drops lawsuit as CMS relents on classification of Opzelura

Incyte has reached a settlement with the Centers for Medicare & Medicaid Services (CMS) regarding rebate criteria for its eczema and vitiligo treatment Opzelura, according to a

Raccontata dafiercepharma.com